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HIV-exposed but uninfected (HEU) infants born to HIV-infected mothers from areas in the world with a high burden of infec-
tious disease suffer higher infectious morbidity andmortality than their HIV unexposed uninfected (HUU) peers. Vaccination
provides protection from infection. The possibility exists that altered response to vaccination contributes to the higher rate of
infection in HEU than in HUU infants. While short-term, cross-sectional studies support this notion, it is unclear whether or not
HEU infants develop long-term protective immune responses following theWHO extended program on immunization (EPI).
Vaccine-specific antibody responses were compared between HEU and HUU infants from 2 weeks until 2 years of age in a longi-
tudinal South African cohort. Total IgG and antibodies specific for Bordetella pertussis,Haemophilus influenzae type b (Hib),
tetanus toxoid, hepatitis B virus (HepB), andmeasles virus were measured at multiple time points throughout the first 2 years of
life. Prevaccine antibodies (maternal antibodies passively acquired) specific for tetanus were lower in HEU than in HUU infants,
while prevaccine antibodies to HepB were higher in HEU than in HUU infants. Both groups responded similarly to tetanus, Hib,
and HepB vaccination. HEU demonstrated stronger pertussis vaccine responses, developing protective titers 1 year earlier than
HUU patients, andmaintained higher anti-tetanus titers at 24 months of age. Vaccine-induced antibodies to measles virus were
similar in both groups at all time points. Our results suggest that the current EPI vaccination program as practiced in South Af-
rica leads to the development of vaccine-specific antibody responses that are equivalent in HEU and HUU infants. However, our
data also suggest that a large fraction of both HEU and HUU South African infants have antibody titers for several infectious
threats that remain below the level of protection for much of their first 2 years of life.
Vaccination is essential to combat infectious mortality andmorbidity in children under 5 years of age (1). Despite the
availability of effective vaccines, 6 million children die from infec-
tious diseases annually, mainly in low- to middle-income coun-
tries where HIV is often prevalent (2, 3). While a lack of access to
vaccines surely is the most important contributor to the high
number of vaccine-preventable deaths in these regions, it is un-
clear if vaccination is equally protective in all children. Globally,
more than 2 million babies are born to HIV-infected mothers
every year (4). Programs for vertical transmission prevention of
HIV (VTP) have reduced vertical infection to well below 10% (5),
therefore nearly 2 million HIV-exposed but uninfected (HEU)
infants are born annually. Recent evidence indicates that HEU
infants are at a higher risk of infectious morbidity and mortality
than their HIV-unexposed, uninfected (HUU) peers (6–12). The
underlying reason(s) for this phenomenon are still unclear but are
possibly multifactorial; severity of maternal HIV disease (13),
avoidance of breastfeeding (14–16), and differences in microbial
exposures (17) have all been postulated. Furthermore, exposure to
HIV itself (18), as well as to antiretroviral drugs for VTP, may also
directly impact the HEU infant’s immune system (19, 20). Subop-
timal response to vaccination thus has been suggested to contrib-
ute to the increased infectious burden of HEU. This notion has
been supported by several studies, which documented low vac-
cine-specific antibody titers in HIV-infected mothers and attenu-
ated vaccine-specific antibody levels in HEU compared to HUU
infants (21–24). These differences have been ascribed to a com-
promise in maternally transferred antibodies, differing antibody
half lives (24), and altered responses to vaccination (21, 22). To
date, however, studies have only investigated vaccine responses in
either short-term cohorts or in cross-sectional analysis (21–24),
thereby not addressing long-term vaccine-induced immunity in
HEU infants (14). A longitudinal analysis of HEU responses to
vaccination is required to better understand how the rapidly ex-
panding population of HEU infants responds to childhood vacci-
nation. To this end, we established a birth cohort study in South
Africa, a country with an antenatal HIV prevalence of 30% (25),
and monitored HEU and HUU infants from 2 weeks up to 2 years
of life (12), evaluating their vaccine-specific immune responses.
Based on the published literature (21, 22, 24), we expected to find
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lower prevaccine-specific antibody titers in the HEU than in the
HUU infants, followed by a higher level of response to certain
vaccines in HEU than in HUU infants after vaccination. However,
given the lack of data, we were not able to predict HEU infants’
immune response to booster doses and the longevity of the result-
ing immune response. Our study aimed to provide this missing
information.
MATERIALS AND METHODS
Cohort composition. A prospective cohort study commenced in March
2009 in Cape Town, South Africa, to evaluate immune function in HEU
and HUU infants over the first 2 years of life (12). The research ethics
committees of Stellenbosch University and the University of British Co-
lumbia both approved the study. Infants of mothers with known HIV
infection status were recruited at birth from the Tygerberg Academic Hos-
pital (TAH) labor ward and evaluated at 0.5, 1.5, 3, 6, 12, 18, and 24
months. HIV infection status of the mothers was confirmed on presenta-
tion at TAH using serological HIV testing algorithms according to the
South African national protocol (26). Infants received their vaccinations
at public health clinics according to the then-applicable Expanded Pro-
gram for Immunization (EPI). These included oral polio vaccine and
Bacille Calmette-Guerin (BCG) vaccine at birth; diphtheria, tetanus tox-
oid (TT), cellular pertussis vaccines (DTP),Haemophilus influenzae type b
(Hib) vaccine, hepatitis B, and oral polio vaccines (OPV) at 6, 10, and 14
weeks; measles vaccine at 9 and 18 months; and DTP as well as OPV
booster doses at 18 months. At each visit, unblinded medical professionals
assessed receipt of immunizations in each infant by evaluating the infant
immunization card.
Laboratory assays. A venous blood sample was collected from the
infants at study visits and immediately transported to the laboratory,
where plasma was frozen at80°C for batch analysis of specific antibody
levels. The HIV-negative status of both HEU and HUU infants was con-
firmed by HIV DNA PCR with an Amplicore HIV-1 DNA test kit, version
1.5 (Roche Diagnostics), at 0.5 and 1.5 months of life and using Cobas
AmpliPrep/Cobas TaqMan HIV-1 test, v2.0, at 3 and 24 months of life.
Quantitative determination of specific IgG levels present in plasma to
Bordetella pertussis, TT, Hib, hepatitis B virus, and measles virus were
performed by standard commercial enzyme-linked immunosorbent as-
says (ELISAs) conducted according to the manufacturers’ instructions.
Specific IgG levels to B. pertussis, TT, and measles virus were evaluated
using Serion ELISA classic kits (ESR120G, ESR108G, and ESR102G; Se-
rion Immunodiagnostica GmbH, Würzburg, Germany). Hib-specific IgG
was measured using VaccZyme human anti-Hib ELISA kits (MK016 and
MK012; The Binding Site Ltd., Birmingham, England). HBsAg-specific
IgG was measured using a human anti-hepatitis B surface antigen quan-
titative ELISA kit (4220-AHB; Alpha Diagnostic International Inc., San
Antonio, TX). As recommended by the manufacturer, vaccine-specific
IgG levels were expressed using the following units: anti-B. pertussis IgG in
FDA units per milliliter, anti-TT IgG in international units per milliliter,
anti-measles virus IgG and anti-HBsAg IgG in milli-international units
per milliliter, and anti-Hib IgG in milligrams per milliliter. Quantitative
determination of total IgG was evaluated at each visit using GenWay hu-
man IgG ELISA kits (GWB-A04A50; Genway Biotech, San Diego, CA);
total IgG levels were measured in milligrams per milliliter. Antibody titers
of 30 FDA U/ml were deemed protective for pertussis, as defined by the
manufacturer. For measles virus, 200 mIU/ml was the cutoff for protec-
tion established by the manufacturer. The minimum protective antibody
titers for tetanus of 0.1 IU/ml (27, 28), for hepatitis B virus (HepB) of 10
mIU/ml (28, 29), and for Hib of 1 mg/ml (28, 30) were considered pro-
tective.
Statistical analysis. Statistical analysis of the antibody levels was per-
formed using Microsoft Excel software (2007). Antibody responses were
log transformed and subjected to unpaired, two-tailed Student’s t tests for
comparison of mean specific antibody levels between HEU and HUU
infants at each time point. For comparison of longitudinal antibody re-
sponses we did not apply a correction for multiple comparisons, as these
comparisons were not independent of one another. Statistical analysis of
the baseline cohort characteristics was performed using R version 2.13.1
(R Foundation for Statistical Computing, Vienna, Austria); continuous
variables were analyzed using the Student t test and the chi-square cate-
gorical variable, and two-sided alpha was set at 0.05.
RESULTS
Participant characteristics. Fifty-nine infants were enrolled at 2
weeks; four were identified as HIV infected by HIV DNA PCR
testing at 2 weeks of age and were excluded from analysis. Thus, 28
HUU infants and 27 HEU infants were retained at the first clinical
visit; 17 HEU and 20 HUU infants were retained throughout the
2-year study. All HEU infants were confirmed to remain HIV
uninfected by HIV DNA PCR at 1.5, 3, and 24 months of age.
There was no significant difference in sex, birth weight, gestational
age, or number retained at follow-up at 2 years between the two
groups (Table 1). All HEU infants but one were exclusively for-
mula fed; all but one HUU infant initiated breastfeeding at birth
and continued breastfeeding with a median duration of exclusive
breastfeeding of 12 weeks. Detailed descriptions of participant
characteristics for this cohort were provided elsewhere (12).
Specific antibody levels.All HEU and HUU subjects were vac-
cinated within the same time frame relative to blood draws for
serological analysis. None of the infants received DTP/Hib or
HepB vaccination prior to the 0.5- and 1.5-month blood draw,
thus antibody levels at these time points are reflective of transpla-
cental maternal antibody transfer. Infants at the 6-month blood
draw were also still measles vaccine naïve, as this vaccine was not
administered until 9 months of age.
Prevaccination, at 0.5 and 1.5 months, HEU infants had overall
lower antibody-specific levels for tetanus, pertussis, and Hib (Fig.
1A, C, E, and G). However, prevaccine, only anti-tetanus levels
were statistically lower in HEU (P  0.025). Conversely, HepB
antibody levels were higher in HEU infants prior to vaccination
(P 0.025), although only one-quarter of HEU infants had levels
considered to be protective.
Vaccine-specific titers of HEU and HUU infants reached sim-
ilar levels after 2 vaccine doses as measured at the 3-month blood
TABLE 1 Baseline infant characteristics by HIV exposure status
Parametera
Infant exposure type
P valueTotal (n 55) HEU (n 27) HUU (n 28)
No. (%) male 22 (40) 7 (26) 15 (54) 0.35
Mean birth weight (95% CI), in g 2,966 (2,857–3,075) 2,945 (2,866–3,024) 2,986 (2,830–3,142) 0.7
Mean gestational age (95% CI), in wk 37.8 (37.1–38.4) 37.7 (36.7–38.7) 37.9 (37.0–38.7) 0.8
No. (%) of infants in follow-up at 24 mo 37 (67) 17 (63) 20 (71) 0.7
a CI, confidence interval.
Reikie et al.
34 cvi.asm.org Clinical and Vaccine Immunology
 o
n







draw. However, at that time point (3 months) the average anti-
body titers reached protective levels in 50% of recipients only
for tetanus, Hib, and HepB, while20% of infants had protective
anti-pertussis antibody levels (Fig. 1B, D, F, and H). Of note, HEU
infants had significantly higher titers of anti-pertussis antibody
after the third dose (by 6 months). As a result, a higher propor-
tion of HEU than HUU infants reached protective levels at 6
months of age; protective anti-pertussis titers in HUU were not
FIG 1 (A, C, E, and G) Specific antibody levels were measured in HEU (black line) and HUU (grey line) infants at 0.5, 1.5, 3, 6, 12, 18, and 24 months of age for
all vaccines except hepatitis B, for which the 18-month time point was omitted (N/A) due to insufficient sample. The total response of the two groups combined
is shown with the dashed line. The vaccine antibody level is indicated on the y axis. Arrows indicate the time of vaccination. The horizontal black line indicates
the minimal antibody level associated with protection. Error bars indicate standard errors of the means (SEM). *, P 0.05; **, P 0.01; ***, P 0.001. (B, D,
F, and H) Individual antibody titers were compared to established minimum protective antibody levels. The proportion of subjects whose titers exceeded the
minimum level for protection are shown for HEU (black bar) and HUU (gray bar) infants.
HIV-Exposed versus Unexposed Infant Vaccine Responses
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achieved until 18 months of age (after the fourth vaccine dose).
Notably, for either group, once protective levels were reached,
antibodies were maintained at or above average protective ti-
ters through 2 years of age.
Individual titers were analyzed within each group to determine
the proportion of subjects with protective antibody titers. Prior to
vaccination, more than 25% of infants in both HEU and HUU
groups had protective levels of anti-pertussis antibodies (Fig. 1B).
More than one-quarter of HEU subjects were also protected from
HepB before vaccination, whereas no HUU infants had protective
anti-HepB titers prior to vaccination (Fig. 1H). In contrast, the
proportion of HUU infants protected from Hib was greater than
that of the HEU group (Fig. 1F). Very few infants in either group
had protective titers of anti-tetanus antibodies prior to their first
vaccination (Fig. 1D).
On average, protective levels of anti-measles virus antibody
were not reached by either the HEU or HUU group until after the
first vaccine dose had been given at 9 months (Fig. 2A). When
measured at 2 years, anti-measles virus antibody titers remained
unchanged following administration of the second dose (admin-
istered at 18 months). The average levels of anti-measles virus
antibody were nearly indistinguishable between the HEU and
HUU groups at all time points throughout the first 2 years of life.
Analyzing the individual subjects’ anti-measles virus antibody re-
vealed fewer than one-quarter of subjects with protective prevac-
cination titers in both groups at 2 weeks, and this dropped further
by 6 weeks. The highest proportion of protected subjects was
found at 12 months in HUU infants and at 18 months in HEU
infants, with approximately three-quarters of subjects protected.
Interestingly, the number of subjects deemed protected decreased
at 2 years only in the HUU group, with only about half maintain-
ing protective measles virus-specific antibody titers (Fig. 2B).
Total immunoglobulin. Total IgG levels were measured at all
time points in order to determine whether detected differences in
vaccine-specific IgG were due to nonspecific differences in total
IgG (e.g., hypergammaglobulinemia) (31). Equivalent total IgG
levels, with age-appropriate physiological hypogammaglobuline-
mia at 1.5 and 3 months, were observed in HEU and HUU infants
(Fig. 3).
DISCUSSION
In this prospective, longitudinal comparison of antibody response
to vaccines administered over the first 24 months, we identified
robust serological responses to the EPI vaccines in both groups.
With the exception of an earlier response to the pertussis vaccine
and a higher anti-tetanus titer at 24 months in HEU than HUU
infants, the vaccine responses were comparable overall in magni-
tude between HEU and HUU infants. This suggests that HEU
infants mount a quantitative response to EPI vaccines similar to
that of HUU infants over the first 2 years of life.
The diminished baseline prevaccine antibody levels for tetanus
(significant) and Hib (not significant) we detected in HEU infants
could be due to lower levels of vaccine-specific antibodies in the
mother, placental dysfunction resulting in decreased antibody
transfer, or decreased half-life of transferred maternal antibodies
(21, 22, 24, 32). On the other hand, the higher levels of prevaccine
HepB antibodies observed in HEU infants likely reflected mater-
nal HepB infection in HIV-infected mothers; indeed, high vari-
ability in the prevaccine HepB antibody levels were observed in
our HEU cohort, suggesting that individual differences, such as
FIG 2 (A) Specific antibody levels were measured in HEU (black line) and HUU (gray line) infants at 0.5, 1.5, 12, 18, and 24 months of age. The total response
of the two groups combined is shown with the dashed line. Arrows indicate the time of vaccination. The horizontal black line indicates the minimal antibody level
associated with protection. The vaccine antibody level is indicated on the y axis. Error bars indicate SEM. (B) Individual antibody titers were compared to
minimum protective antibody levels. The proportion of subjects whose titers exceeded the minimum level for protection were shown for HEU (black bar) and
HUU (gray bar) infants.
FIG3 Total IgG levels were measured in HEU (gray bar) and HUU (black bar)
infants at 0.5, 1.5, 3, 6, and 12 months of age. The total IgG level is indicated on
the y axis. Error bars indicate SEM. P 0.05 indicated significance.
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maternal HepB infection, are involved. This, however, was not
formally evaluated.
HEU infants developed significantly higher anti-pertussis ti-
ters than HUU infants at 6 and 12 months of age, extending the
previous observation of Jones et al., who showed increased re-
sponse at 4 months of age (22). Anti-B. pertussis titers had already
reached protective levels in HEU infants by 6 months after receiv-
ing only 3 doses in total. HEU infants therefore may be protected
from pertussis infection sooner than HUU infants, who attained
protective titers of anti-B. pertussis antibody after the 18-month
booster. This could relate to decreased maternal antibody inter-
ference during vaccine priming secondary to a lower level of pla-
centally transferred antibodies in HEU than HUU infants (33).
Overall, the period of suboptimal protection from pertussis in
infancy was unexpectedly long for both HEU and HUU infants, 6
to 12 months, requiring 3 to 4 doses of vaccine. Since the vaccine
antibody response to Hib, tetanus, hepatitis B, and measles virus
reached protective levels after 1 or, at most, 2 doses, an overall
lower general immune response to vaccination in our subjects
seems unlikely to be the cause for the suboptimal response to
pertussis vaccination. The most critical period for severe pertussis
is early in life; the prolonged gap in protective levels of antibodies
of South African infants thus appears worthy of further investiga-
tion.
The prospective, longitudinal nature of our study, and espe-
cially the extension up to 24 months of age, provide the much-
needed insight into long-term vaccine-induced protection in this
highly vulnerable population. However, there are several limita-
tions to our study. First and foremost, our sample size was small.
However, it should be noted that our results confirm previous
cross-sectional reports on vaccine responses in HEU infants (21,
22), and in their aggregate they strongly support our overall con-
clusion. Second, the feeding mode differed significantly between
HUU and HEU infants, as formula feeding of HEU infants was
prevalent in the Western Cape during our study. Breast- versus
bottle feeding is known to influence vaccine responses. Third, we
did not determine maternal antibody titers to the measured vac-
cine antigens, which clearly could have differed between HIV-
infected and uninfected mothers and influenced the vaccine re-
sponse of their respective infants. However, the aim of our study
was to define the long-term vaccine response of HEU infants com-
pared to HUU infants, not the cause of the differences. Differences
in feeding preference reflect the reality of feeding patterns of HEU
infants in South Africa (and elsewhere) and, along with differ-
ences in maternal antibody titers, may have contributed to differ-
ences in vaccine responses between HEU and HUU infants. Lastly,
we did not collect information about the clinical status of HIV-
infected mothers, who might have influenced their infant’s re-
sponse to vaccination, thus we cannot comment on the impact of
maternal HIV disease on HEU infant vaccine responses.
For comparison of antibody responses, we did not apply a cor-
rection for multiple comparisons, as these comparisons were not
independent of one another; this must be considered when inter-
preting our results. We reasoned that a given vaccine-specific an-
tibody response would be interrelated when comparing time
points for reasons such as interference from preexisting serum
antibody levels and preestablished B cell memory largely dictating
the strength of booster responses. Furthermore, general immune
attributes that impact an individual’s vaccine response likely apply
to other vaccines. Lastly, we did not perform functional studies
regarding antibody responses following immunization. This is
important, as, for example, a study comparing responses to the
7-valent pneumococcal vaccine in HEU and HUU infants showed
similar responses in HEU and HUU infants for 6 of 7 serotypes
and an even better response than HUU infants to one serotype
(6B). However, upon evaluation of qualitative function by the
opsonophagocytic killing assay, HEU infants in fact required
higher concentrations of antibody for 50% killing activity against
one of the serotypes (19F) (34). Thus, we cannot exclude qualita-
tive differences between HEU and HUU infants to the EPI vac-
cines we tested.
In conclusion, aside from and in spite of selected differences of
prevaccination antibody levels, HEU infants responded quantita-
tively at least as well as HUU infants to current standard EPI vac-
cination.
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